Biomea Fusion/BMEA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Biomea Fusion

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

Ticker

BMEA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Thomas Butler

Employees

110

Headquarters

Redwood city, United States

Biomea Fusion Metrics

BasicAdvanced
$378M
Market cap
-
P/E ratio
-$3.57
EPS
-
Beta
-
Dividend rate
$378M
$43.69
$8.13
1M
5.843
-90.54%
-116.52%
-107.35%
2.794
2.795
-10.94%

What the Analysts think about Biomea Fusion

Analyst Ratings

Majority rating from 8 analysts.
Buy

Biomea Fusion Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$39M
12.07%
Profit margin
0.00%
NaN%

Biomea Fusion Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 9.64%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.80
-$0.98
-$1.09
-
Expected
-$0.88
-$0.82
-$0.85
-$0.99
-$1.07
Surprise
-20.01%
-2.81%
15.09%
9.64%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Biomea Fusion stock?

Biomea Fusion (BMEA) has a market cap of $378M as of June 17, 2024.

What is the P/E ratio for Biomea Fusion stock?

The price to earnings (P/E) ratio for Biomea Fusion (BMEA) stock is 0 as of June 17, 2024.

Does Biomea Fusion stock pay dividends?

No, Biomea Fusion (BMEA) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Biomea Fusion dividend payment date?

Biomea Fusion (BMEA) stock does not pay dividends to its shareholders.

What is the beta indicator for Biomea Fusion?

Biomea Fusion (BMEA) does not currently have a Beta indicator.

What is the Biomea Fusion stock price target?

The target price for Biomea Fusion (BMEA) stock is $53, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Biomea Fusion stock

Buy or sell Biomea Fusion stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing